Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Mammoth Biosciences and GSK partner on CRISPR-based COVID-19 test
by Megha Satyanarayana
May 21, 2020
| A version of this story appeared in
Volume 98, Issue 20
Mammoth Biosciences will partner with GSK Consumer Healthcare to create a handheld, at-home COVID-19 test. The test is based on CRISPR, a gene-editing technology they are deploying to detect viral RNA from SARS-CoV-2, the coronavirus that causes COVID-19. Mammoth says the test will produce results from a nasal swab in under 20 min. The companies expect to apply later this year for a US emergency use authorization.
C&EN has made this story and all of its coverage of the coronavirus epidemic freely available during the outbreak to keep the public informed. To support our journalism, become a member of ACS or sign up for C&EN's weekly newsletter.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter